Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Life Sci ; 63(13): 1127-36, 1998.
Artículo en Inglés | MEDLINE | ID: mdl-9763208

RESUMEN

Diabetes (type I and type II) affects approximately 13 million people in the United States. Delayed and incomplete healing of wounds can be a major problem for diabetic patients. Macrophages are an important cell in the complex process of wound repair representing the major source of cytokines throughout the wound healing process. Cytokines mediate many of the cellular responses critical to timely wound repair. It has been suggested that diabetes impairs wound healing through disruption of local cytokine production. We previously demonstrated that platelet-derived growth factor B chain (PDGF-B) levels are deficient at the wound site of diabetic rats. In the present study, we measured the levels of several marker cytokines released from cultured peritoneal macrophages of diabetic, nondiabetic hyperlipidemic, and normal rats. The diabetic condition was associated with a generalized reduction of macrophage cytokine release. Nondiabetic hyperlipidemic animals demonstrated similar cytokine reduction supporting the hypothesis that elevated serum lipids are the primary determinants of diabetes-induced reductions in macrophage cytokine release. Thus, manipulation of serum lipids may be a therapeutically useful modality for controlling macrophage cytokine release in the inflammatory and/or wound environment.


Asunto(s)
Citocinas/metabolismo , Diabetes Mellitus Experimental/fisiopatología , Lipoproteínas LDL/sangre , Macrófagos Peritoneales/metabolismo , Triglicéridos/sangre , Animales , Glucemia/metabolismo , Células Cultivadas , Diabetes Mellitus Experimental/sangre , Diabetes Mellitus Experimental/metabolismo , Ensayo de Inmunoadsorción Enzimática , Sustancias de Crecimiento/metabolismo , Hiperlipidemias/sangre , Hiperlipidemias/metabolismo , Hiperlipidemias/fisiopatología , Lipopolisacáridos/farmacología , Macrófagos Peritoneales/efectos de los fármacos , Masculino , Ratas , Ratas Sprague-Dawley , Estimulación Química
3.
J Natl Cancer Inst ; 55(5): 1085-7, 1975 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-173860

RESUMEN

Female Wistar rats were given a single oral dose of aflatoxin B1, either alone or with a large amount of riboflavin. Biochemical and histologic studies were performed for 30 months. Nine animals of 19 in the aflatoxin-treated group and only 5 of 18 in the riboflavin-aflatoxin-treated group developed hepatomas. The number of rats was insufficient for tests of statistical significance to be fruitful. Urinary excretion of tryptophan metabolites was studied in aflatoxin- and riboflavin-treated rats after an oral administration of 10 mg tryptophan/100 g rat. Riboflavin did not affect the percentage of aflatoxin-treated animals with abnormal urinary excretion patterns, but did increase the magnitude of the disturbances in elimination of kynurenic and xanthurenic acids. The hepatic tryptophan-oxygenase activity was increased only in the two groups given riboflavin, and the levels of nucleic acids were the same in all groups.


Asunto(s)
Aflatoxinas , Carcinoma Hepatocelular/inducido químicamente , Neoplasias Hepáticas/inducido químicamente , Riboflavina/farmacología , Triptófano/metabolismo , Aflatoxinas/farmacología , Aflatoxinas/toxicidad , Animales , Femenino , Ácido Quinurénico/orina , Hígado/metabolismo , Neoplasias Experimentales/inducido químicamente , Ratas , Triptófano/orina , Triptófano Oxigenasa/metabolismo , Xanturenatos/orina
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA